key: cord-1030502-zzt1i3mh
authors: Yee, JoAnn L.; Van Rompay, Koen K. A.; Carpenter, Amanda B.; Nham, Peter B.; Halley, Bryson M.; Iyer, Smita S.; Hartigan‐O'Connor, Dennis J.; Miller, Christopher J.; Roberts, Jeffrey A.
title: SARS‐CoV‐2 surveillance for a non‐human primate breeding research facility
date: 2020-07-03
journal: J Med Primatol
DOI: 10.1111/jmp.12483
sha: a9c2798aaf80c7b25a2a0cc35525a562c80298fe
doc_id: 1030502
cord_uid: zzt1i3mh

BACKGROUND: The emergence of SARS‐CoV‐2 and the ensuing COVID‐19 pandemic prompted the need for a surveillance program to determine the viral status of the California National Primate Research Center non‐human primate breeding colony, both for reasons of maintaining colony health and minimizing the risk of interference in COVID‐19 and other research studies. METHODS: We collected biological samples from 10% of the rhesus macaque population for systematic testing to detect SARS‐CoV‐2 virus by RT‐PCR and host antibody response by ELISA. Testing required the development and validation of new assays and an algorithm using in laboratory‐developed and commercially available reagents and protocols. RESULTS AND CONCLUSIONS: No SARS‐CoV‐2 RNA or antibody was detected in this study; therefore, we have proposed a modified testing algorithm for sentinel surveillance to monitor for any future transmissions. As additional reagents and controls become available, assay development and validation will continue, leading to the enhanced sensitivity, specificity, accuracy, and efficiency of testing.

of this protection is not known. There are still many uncertainties about the short-or long-term health effects of SARS-CoV-2 on NHP. Thus, it is imperative to reduce the risk of a SARS-CoV-2 outbreak at a NHP research facility for several reasons, including (a) its potential harmful effects on general health of the breeding colony, (b) possible interference with specific research projects, and (c) suitability of infected and/or immune animals for future SARS-CoV-2 research.

Given the susceptibility of NHPs and presumed lack of pre-existing immunity, the California National Primate Center (CNPRC) at the University of California, Davis (UCD), adopted management practices to reduce the risk of virus introduction and transmission and initiated surveillance testing to monitor for SARS-CoV-2 in the colony. The CNPRC had a measles outbreak in 1987 that resulted in extensive colony morbidity and mortality. 13 This historical event heightened concern at CNPRC about the possible impact of any SARS-CoV-2 introduction.

Following identification of SARS-CoV-2 in a few individuals in Northern California, with support of the UCD administration, on March 4, 2020, the CNPRC implemented practices to reduce risk, including denying admission to visitors, interns, students, and non-employees. All public tours, demonstrations, classes, and any vendor-or employee-sponsored visits to CNPRC were canceled.

In addition, on-site staffing was reduced from approximately 300 people to essential personnel only, who were required to modify their practices to incorporate new CDC guidelines for hygiene, personal protective equipment (PPE), and physical distancing. Access to both the indoor vivarium and outdoor vivarium was restricted to employees with work-related activities. New signage reinforcing entry restrictions and PPE requirements was posted. Upon issuance of shelter-in-place directives from the Yolo County public health department, on March 18 UCD suspended normal campus operations and moved to remote student instruction and employee work. All non-critical, on-site research activities were ramped down. From February 22 to May 18, 2020, 1794 human cases of COVID-19 were confirmed in Yolo, Sacramento, and Solano counties surrounding the CNPRC. 14-16 Human-to-human transmission including community spread beyond travel or household contact acquisition has been documented in this region, where the majority of CNPRC employees reside. Therefore, there is risk of infection in, and transmission between, facility staff and captive non-human primates.

F I G U R E 1 Non-human primates at CNPRC are at risk of SARS-CoV-2 infection from humans primarily, but also from susceptible feral animals (such as cats 35 ). Reducing entry of people to CNPRC, reduced operations, limiting inter-individual (human-to-animal, human-tohuman, animal-to-animal) contact, proper PPE and distancing, and the setup of a surveillance testing program for humans and animals are important components of the infection control program. Special barrier rooms have been set up to house animals screened and removed from either the conventional non-SPF or SPF colonies with the goal of keeping them uninfected, so that they can subsequently be used for SARS-CoV-2 inoculation studies in biosafety level 3 (BSL3) setting (icons by Adioma and Iconfinder) Transmission risks to capƟve nonhuman primate colonies and development of risk miƟgaƟon program.

The CNPRC drafted a sentinel surveillance plan including laboratory testing to detect both the presence of the virus and the development of antiviral antibodies in the non-human primate colony. In addition, we endeavored to develop testing methods that would not add pressure to the already overloaded supply chain used in human diagnostic medicine. When it becomes more widely available, accurate testing of humans with occupational exposure to the non-human primate colony for past or present SARS-CoV-2 infection will be an additional, adjunct surveillance tool to reduce the risk of NHP infection.

Our Primate Assay Laboratory (PAL) developed the capacity to conduct both serology testing for antibody to SARS-CoV-2 and RT-PCR testing for the virus. Antibody responses may be observed as early as 14 days post-infection. 4 SARS-CoV-2 research) were also collected. Due to the scarcity of available resources for antibody and PCR testing, this initial study was limited to these animals.

All animals were maintained in fully AAALAC-accredited facilities in accordance with the Animal Welfare Act, Regulations, and the Guide for the Care and Use of Laboratory Animals. 23, 24 The following samples were collected: (a) nasal and oropharyngeal swabs using either a Universal Viral Transport Collection Kit (Becton Dickinson, Franklin Lakes, NJ) or sterile polyester tipped 6" applicator sticks (Puritan, Guilford, ME) submerged in 1 mL of TRIzol Reagent (Thermo Fisher Scientific); (b) approximately 1 g feces placed in a sterile plastic vial;

and (c) 5 mL whole blood (without anticoagulant). TRIzol is a monophasic solution of phenol and guanidine isothiocyanate commonly used to fix and preserve blood and body samples for nucleic acid isolation. The whole blood was centrifuged at 1000 g for 15 minutes to separate serum for antibody testing. The samples were stored frozen at ≤−80°C until tested. A subset of surveillance samples collected were selected and tested on a weekly basis to provide the widest distribution possible, that is, to maximize the number of indoor and outdoor housing types and locations represented. Any reactive samples were rechecked by repeat sampling and testing.

SARS-CoV-2 strain Wuhan-Hu-1 recombinant spike antigen-coated microtiter plates, commercially available from Xpress Bio, were used for antibody screening. The manufacturer describes the antigen as a mixture of recombinant spike S1 and spike S2 glycoproteins produced in HEK293 cells and purified with Protein G chromatography.

The S1 protein contains the amino acids 1-674 with a C-terminal sheep Fc-tag, and the S2 protein has amino acids 685-1211 with a C-terminal sheep Fc-tag. The spike S1 protein contains the receptor-binding domain that has affinity to the angiotensin-converting 

Viral RNA was extracted from the oral and/or nasopharyngeal swabs using viral total nucleic acid purification reagents on the semi-automated Maxwell RSC Instrument (Promega) following the manufacturer's instructions. 200 µL of swab eluate was lysed and proteinase K treated for 10 minutes at 56°C, before being added to a reagent cartridge and loaded into the instrument for automated extraction of nucleic acid using paramagnetic particles as a mobile solid phase for sample capture, purification, washing, and elution in 50 µL final volume.

5 µL of viral RNA was transcribed to cDNA and subsequently ampli- Sera from 120 additional monkeys were collected and tested for antibody without parallel PCR testing due to a lack of collection swabs.

PCR testing was performed on nine monkeys for which serum could not be collected. Repeat samples from the same animals were collected on later dates for 20 PCR and 33 antibody determinations.

No changes in reactivity were observed in the repeat testing. The study population included 157 males and 228 females ranging from 1 to 24 years of age. Fecal samples were archived frozen at −80°C for future studies.

No SARS-CoV-2 antibody was detected. The data generated using the Xpress Bio Spike S1, S2 antigen are shown in Figure 2 In addition, no reactivity to seasonal coronaviruses 229E and NL63 was detected. By comparing reactivities to a panel of antigens prepared in different cell lines, they were able to conclude that the observed reactivity to spike S1, S2 antigen was due to reactivity to either the HEK cell line or the sheep Fc purification tag used in its production. Figure 3 displays additional, parallel data obtained from the ELISAs developed in the PAL laboratory.

Although the data are limited, differences in antigen preparations were observed and not all performed acceptably. Despite titrations to optimize antigen concentrations, blocking protocols, sample and conjugate dilutions and buffers, incubation times, and temperatures, we could not clearly distinguish positive from negative samples with the SB spike antigen. We speculate that this could be caused by non-SARS-CoV-2-specific reactivity due to this recombinant protein epitope or its production method. Assay development and validation work are continuing with the other antigens. The antibody data are summarized in Table 1 .

No SARS-CoV-2 RNA was amplified from any of the monkeys. As it became difficult to acquire the Universal Viral Transport Collection for TRIzol samples ( Figure 4B ). The broader range correlates with more samples tested. All values met the acceptable CDC criterion of less than 35.0. 29 These ranges indicated comparable recovery of RNA from samples collected in either system. As compared to processing of a fresh sample, Ct values for N1, N2, and OSM Ct did not change F I G U R E 2 Xpress Bio antigen ELISA results for positive control, historical (collected pre-2020), and current 2020 surveillance samples. The delta OD value represents the difference in reactivity between SARS-CoV-2 S1,2 antigen and an uninfected cell control. A dashed line below the lowest positive control value highlights the range of negative values and outliers in the historical and surveillance groups significantly following 1-week storage at room temperature, 4°C, and −80°C ( Figure 4C ). The loss of reactivity to N1 and N2 was only slight over 3 freeze-thaw cycles ( Figure 4D ). Initially, samples were ampli- 

No detection of SARS-CoV-2 antibody or RNA in this 10% sentinel surveillance of the CNPRC macaque colony suggests that the current colony management practices, including restricted access and PPE, are sufficient. However, it is difficult to adequately assess the extent of risk reduction achieved because the prevalence of infection in facility staff could not be clearly determined under the current conditions of limited human testing. Currently, PPE in routine use at the CNPRC includes standard surgical masks and face shields, which can reduce respiratory pathogens but may not be as effective as NIOSH-approved respirators. 30 Until we better F I G U R E 3 Performance of ELISAs formatted with commercially available SARS-CoV-2 spike and nucleocapsid antigens on a subset of current 2020 surveillance and positive control samples. The IT spike antigen is aa1-1208 from BetaCoV/Wuhan/IVDC-HB-05/2019 expressed in 293 cells; the SB spike antigen is a DNA sequence encoding the 2019-nCoV spike S1 + S2 expressed in baculovirus-insect cells. The IT NC is the nucleocapsid protein from COVID-19/ Wuhan expressed in E. coli; the SB NC antigen is a DNA sequence encoding the 2019-nCoV nucleocapsid protein expressed in baculovirus-insect cells

Xpress Bio Spike S1 + S2 409 3

Sino Biological Spike S1 + S2 18 9

Immune Technology Spike trimer 69 0

Sino Biological Nucleocapsid 18 0

Immune Technology Nucleocapsid 69 1

Note: In addition, 40 samples collected and archived prior to 2020 were tested using the Xpress Bio spike antigen S1 + S2. 1 was reactive.

understand the epidemiology of SARS-CoV-2 in the human population, it is prudent to assume that non-human primate populations are at risk of infection from humans. That risk makes the development of an active surveillance program essential. The collection and testing of these samples provide valuable baseline data for ongoing monitoring. With continued prevalent cases in the human population (including those who have potential contact with the non-human primate colony), continued testing of at least a representative sample of the colony on a regular basis will be necessary. Given the logistical and resource limitations and lack of active infection, antibody testing will be used for general ongoing surveillance, with RNA detection reserved for animals showing respiratory signs, relocation to sensitive locations, and pre-research study screening. Increased, widely available human testing to determine the accurate prevalence and transmission rates will allow for better informed risk assessment and refinement of the surveillance program for the CNPRC non-human primate colony. Thus, surveillance testing for employees is being proposed to complement the NHP colony surveillance efforts.

Important experience with various commercially available and laboratory-developed reagents has been gained from this study.

Using the currently available assays, we will apply the algorithm described in Figure 6 to ongoing testing at the CNPRC. This algorithm considers the purpose of testing and prioritizes the use of resources IgM antibody testing to determine past vs current infection may also be useful. The sensitivity and specificity of these assays is still under evaluation.

controls. We have other research studies in progress developing primer and probe sets for additional gene sequences. We will be able to evaluate which and how many are necessary to further enhance the accuracy and efficiency of virus detection.

Working Group (PDWG) has shared testing guidance and outlined a general testing algorithm on their website. 31 We will use this in- The ability of the biomedical research community to end the COVID-19 pandemic will depend not only on the availability of NHP, but also more importantly on the availability of NHP that are specific pathogen-free for SARS-CoV-2. Thus, it is important for NHP research facilities to develop a robust surveillance program and a plan for a response to the detection of SARS-CoV-2 in their colony. The CNPRC has established a barrier colony of SARS-CoV-2-negative animals to ensure availability of SPF animals for future COVID-19 research.

Colonies of outdoor housed primates are potentially at risk from exposure to other species of wildlife that may be susceptible to SARS-CoV-2 infection. However, the most likely route of introduction of SARS-CoV-2 into a non-human primate colony remains to be from employees and visitors from the community. Thus, the success of surveillance and emergency response plans to prevent and control SARS-CoV-2 infection in NHP colonies also depends on our ability to integrate these NHP facility control measures with medical and public health programs that target SARS-CoV-2 in human communities. The programs and ideas described in this manuscript can help to bridge this gap and promote the One Health approach to society's effort to defeat the COVID-19 pandemic. research team provided helpful discussion and consultation.

Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic

Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility-King County

Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)

Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. bioRxiv

Comparison of SARS-CoV-2 infections among 3 species of non-human primates

Development of an inactivated vaccine candidate for SARS-CoV-2

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Age-related rhesus macaque models of COVID-19

Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Epizootic measles at the CRPRC

?appid =055f8 1e9fe 154da 58602 57e3f 2489d67

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence

A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT

COVID-19 testing: the threat of false-negative results

Specific pathogen free macaque colonies: a review of principles and recent advances for viral testing and colony management

A high through-put assay for circulating antibodies directed against the S protein of severe acute respiratory syndrome corona virus 2

Animal Welfare Act as Amended 7 USC

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets

Development of a generic real-time PCR assay for simultaneous detection of proviral DNA of simian Betaretrovirus serotypes 1, 2, 3, 4 and 5 and secondary uniplex assays for specific serotype identification

Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis

Is the coronavirus airborne? Experts can't agree

Transmission of SARS-CoV-2 in domestic cats

SARS-CoV-2 surveillance for a non-human primate breeding research facility